0
0

Increasing Transparency in Generic Drug Applications Act

3/14/2024, 12:02 AM

Congressional Summary of S 4338

Increasing Transparency in Generic Drug Applications Act

This bill requires the Food and Drug Administration to inform generic drug applicants, upon request or during review, whether the drug is qualitatively and quantitatively the same as the listed brand-name drug (and if not, the reasons why).

Current Status of Bill S 4338

Bill S 4338 is currently in the status of Bill Introduced since May 26, 2022. Bill S 4338 was introduced during Congress 117 and was introduced to the Senate on May 26, 2022.  Bill S 4338's most recent activity was Read twice and referred to the Committee on Health, Education, Labor, and Pensions. as of May 26, 2022

Bipartisan Support of Bill S 4338

Total Number of Sponsors
1
Democrat Sponsors
1
Republican Sponsors
0
Unaffiliated Sponsors
0
Total Number of Cosponsors
1
Democrat Cosponsors
0
Republican Cosponsors
1
Unaffiliated Cosponsors
0

Policy Area and Potential Impact of Bill S 4338

Primary Policy Focus

Health

Potential Impact Areas

- Administrative law and regulatory procedures
- Department of Health and Human Services
- Drug safety, medical device, and laboratory regulation
- Prescription drugs

Alternate Title(s) of Bill S 4338

Increasing Transparency in Generic Drug Applications Act
Increasing Transparency in Generic Drug Applications Act
A bill to provide for increased transparency in generic drug applications.

Comments